Lantos appoints CEO, closes Series B round

Lantos Technologies has named Jeffrey Leathe as its new chairman and CEO. The news comes as the company, which is developing a intra-aural 3D scanner providing fast, minimally invasive mapping of the human ear canal, announced the closing of a $4.1 million Series B financing by existing investors Catalyst Health Ventures, Excel Venture Management and Mass Medical Angels. The funding will support the development of the world's first real-time 3D ear canal scanning technology that will enable custom fit audio devices such as hearing aids, earphones and noise-canceling devices.

Leathe previously was chairman and CEO of Biocius Life Sciences and a senior executive at BioTrove, a privately held genomics products company. From 1990-2003, Jeff was the EVP of Apogent Technologies, according to a Lantos release.

"I am excited to be joining the Lantos team as the company prepares for clinical trials and regulatory filings in advance of its first product launch expected in 2012," Leathe said in a statement. "Intra-aural scanning is seen as the holy grail of audiology and with the Lantos technology, team and additional funding, this dream is becoming closer to reality for the industry."

The company also announced that founding Lantos CEO Shahid Azim will become senior VP, new market development, primarily focusing on consumer applications.

- check out the Lantos Technologies release

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.